

05-25-01

A

Box-SEQ

05/24/01
j1055 U.S. PTO

Docket No. 3053-4091US1

Express Mail No. EL 853 256 340 US



27123

PATENT TRADEMARK OFFICE

↑AFFIX CUSTOMER NO. LABEL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL (37 C.F.R. §1.53(b))

j1046 U.S. PTO
09/866020
05/24/01

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- (1) Steven I. DWORETZKY
43 High Meadow Lane
Middlefield, CT 06455 USA;
- (2) Chandra S. RAMANATHAN
41 Alison Avenue
Wallingford, CT 06492 USA;
- (3) Joanne T. TROJNACKI
259 Weatherly Trail
Guilford, CT 06437 USA;
- (4) Christopher G. BOISSARD
73 Oxbow Lane
Northford, CT 06472 USA; and
- (5) Valentin K. GRIBKOFF
142 Williams Road
Wallingford, CT 06492 USA

☐ Additional inventors are listed on a separate sheet

For: **HUMAN KCNQ5 POTASSIUM CHANNELS, METHODS AND
COMPOSITIONS THEREOF**

09866020-052401

Enclosed Are:

76 total pages of Application, including:
66 page(s) of Specification
9 page(s) of Claims
1 page(s) of Abstract
26 sheets of ☒ Formal ☐ Informal Drawings
4 page(s) of Declaration and Power of Attorney

- ☒ Unsigned
☐ Newly Executed
☐ Copy from prior application
☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)

☐ **REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)**

As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).

☐ Incorporation by Reference:

- ☐ The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

☐ Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b))

Signed statement attached deleting inventor(s) named in the prior application serial no. _____, filed _____.

☐ Microfiche Computer Program (Appendix)

- ☒ 22 pages of Sequence Listing
☒ Computer readable disk containing Sequence Listing
☒ Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same

☐ Assignment Papers (assignment recordation cover sheet and assignment document; _____ total pages)

- ☐ A check in the amount of \$40.00 for recording the Assignment
☐ Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No. _____.
☐ Assignment Papers filed in the parent application Serial No. _____

☐ Certification of chain of title pursuant to 37 C.F.R. §3.73(b)

- ☐ Priority is claimed under 35 U.S.C. §119 for:
Application No(s). _____, filed _____, in _____ (country).
- ☐ Certified Copy of Priority Document(s) [_____]
 - ☐ filed herewith
 - ☐ filed in application Serial No. _____, filed _____.
- ☐ English translation document(s) [_____]
 - ☐ filed herewith
 - ☐ filed in application Serial No. _____, filed _____.
- ☒ Priority is claimed under 35 U.S.C. §119(e) for:
Provisional Application No. 60/207,389, filed May 26, 2000.
- ☐ Information Disclosure Statement
 - ☐ Copy of [_____] cited references
 - ☐ PTO Form-1449
 - ☐ References cited in parent application Serial No. _____, filed _____.
- ☐ Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
 - ☐ A copy of related pending U.S. Application(s) Serial No(s): _____, filed _____, respectively, is attached hereto.
 - ☐ A copy of related pending U.S. Application(s) entitled, _____, filed _____ to inventor(s) _____, respectively, is attached hereto.
 - ☐ A copy of each related application(s) was submitted in parent application serial no. _____, filed _____.
- ☐ Preliminary Amendment
- ☒ Return receipt postcard (MPEP 503)
- ☐ This is a ☐ continuation ☐ divisional ☐ continuation-in-part of prior application serial no. _____, filed _____, to which priority under 35 U.S.C. §120 is claimed.
 - ☐ Cancel in this application original claims _____ of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
 - ☐ A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).
- ☐ The status of the parent application is as follows:
 - ☐ A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until _____.
 - ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
 - ☐ No Petition for Extension of Time and Fee therefor are necessary in the co-

pending parent application.

- ☐ Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the parent application to this application
- ☐ Amend the specification by inserting before the first line the sentence:
This is ☐ continuation ☐ divisional ☐ continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00
Total Claims	188- 20 =	168x	\$18.00/ \$9.00	\$ 3024.00
Independent Claims	10- 3=	7x	\$80.00/ \$40.00	\$ 560.00
<input checked="" type="checkbox"/> Multiple Dependent Claims		If marked, add fee of \$270.00 (\$135.00)		\$ 270.00
TOTAL:				\$ <u>4294.00</u>

- ☐ Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$_____.
- ☒ A check in the amount of \$4294.00 in payment of the application filing fees is attached.
- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4091US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: May 24, 2001

By:

Leslie Serunian
Leslie A. Serunian
Registration No. 35,353

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

0906020 052404
T04250" 02099250



27123

PATENT TRADEMARK OFFICE

Docket No. 3053-4091US1**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): S. I. DWORETZKY et al.

Group Art Unit: To Be Assigned

Serial No.: To Be Assigned

Examiner: To Be Assigned

Filed: Herewith (May 24, 2001)

For: **HUMAN KCNQ5 POTASSIUM CHANNELS, METHODS AND COMPOSITIONS THEREOF****EXPRESS MAIL CERTIFICATE**Express Mail Label No.: **EL 853 256 340 US**Date of Deposit: **May 24, 2001**


I hereby certify that the following attached paper(s) and/or fee(s)

1. Application Transmittal under 37 CFR §1.53(b) (5 pages);
2. Utility Application containing 76 total pages, including 66 pages of Specification, 9 pages of Claims, and 1 page of Abstract;
3. Figures 1A/1D through 18A/18B (26 sheets);
4. Sequence Listing (22 pages);
5. 3.5 inch floppy disk containing Sequence Listing;
6. Statement of Identity under 37 CFR §1.821(f), (1 page);
7. Application Fee (check for \$4,294.00);
8. Combined Declaration & Power of Attorney (unexecuted) (4 pages);
9. Return Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

F. J. Garcia

(Typed or printed name of person mailing papers(s) and/or fee)



(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

623555 v1

EL 853 256 340 US



27123

PATENT TRADEMARK OFFICE

PATENT

Docket No.: 3053-4091US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Steven DWORETZKY et al.

Serial No. : To Be Assigned Group Art Unit: TBA

Filed : (Herewith, May 24, 2001) Examiner: TBA

For : **HUMAN KCNQ5 POTASSIUM CHANNEL, METHODS AND COMPOSITIONS THEREOF**

Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §1.821(f) OR §1.825(b)

Dear Sir:

I hereby certify that:

- [X] The paper Sequence Listing and computer readable form of the Sequence Listing submitted herewith are identical (37 C.F.R. §1.821(f)).
- [] The substitute paper Sequence Listing and substitute computer readable form of the Sequence Listing submitted herewith are identical. No new matter is included. (37 C.F.R. §1.825(b)).

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Date: May 24, 2001

By: Leslie Serunian
Leslie Serunian
Reg. No. 35,353

Correspondence Address:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800 (Telephone)
(212) 751-6849 (Facsimile)

T 04250 02099860